Evidence map›Paper›PMID 41212906›Full record

ArticlePLoS pathogens2025

Genomic and epidemiologic characteristics of SARS-CoV-2 persistent infections in California, January 2021 - July 2023.

John M Bell, Jesse Elder, Rahil Ryder, Emily A Smith, Michelle Scribner, Sabrina Gilliam, Deva Borthwick, Megan Crumpler, Jacek Skarbinski, Christina Morales and 1 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

John M BellViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.
Jesse ElderViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.
Rahil RyderViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.
Emily A SmithTheiagen Genomics, Highlands Ranch, Colorado, United States of America.
Michelle ScribnerTheiagen Genomics, Highlands Ranch, Colorado, United States of America.
Sabrina GilliamViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.
Deva BorthwickCOVID Control Branch, Division of Communicable Disease Control, CDPH, Richmond, California, United States of America.
Megan CrumplerOrange County Public Health Laboratory, Santa Ana, California, United States of America.
Jacek SkarbinskiDepartment of Infectious Diseases, Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America.
Christina MoralesViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.
Debra A WadfordViral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health (CDPH), Richmond, California, United States of America.ORCID 0000-0002-8630-427X

Funding

NCEZID CDC HHS U01 CK000539
6 · The paper itself

Abstract

Novel SARS-CoV-2 variants demonstrating considerable intra-host evolution emerged throughout the pandemic. The persistent infections thought to give rise to these variants, however, have been difficult to identify at scale. This study sought to detect and characterize persistent infection cases in California using routine epidemiologic and genomic surveillance data. We identified 69 persistent infection cases with collection dates between January 2021 and July 2023 ranging from 21 to 400 days in duration, with an average of 44 days. Significant differences were identified in age distribution, sex, hospitalizations, and deaths between persistent infection cases and all sequenced California SARS-CoV-2 cases. Underlying health conditions were identified for the majority of cases with available medical records. In these cases, the Spike receptor binding domain was enriched for nonsynonymous mutations, and these mutations demonstrated convergent evolution indicative of immune evasion and were observed in previous persistent infections. We describe a 400-day B.1.429 infection that demonstrates substantial intra-host evolution, and a BA.5.11 persistent infection revealing apparent competition between two intra-host viral subpopulations. By establishing a framework for detecting persistent infections, this study lays the groundwork for other public health organizations to monitor and investigate highly divergent SARS-CoV-2 viruses.

Indexed as

COVID-19Persistent InfectionAdolescentAdultAgedAged, 80 and overCaliforniaComorbidityEvolution, MolecularFemaleHumansMaleMiddle AgedMutationPandemicsSARS-CoV-2Spike Glycoprotein, Coronavirus

Identifiers

PMID41212906
PMCPMC12614806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.